NCT01051414View on ClinicalTrials.gov

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

May 31, 2012

Conditions
Hepatitis C Infection
Interventions
DRUG

BMS-790052

Tablets, Oral, 60 mg, daily, 24 weeks

DRUG

BMS-650032

Tablets, Oral, 1200 mg, daily, 24 weeks

Trial Locations (4)

2138587

Local Institution, Kawasaki-Shi

734-0037

Local Institution, Hiroshima

060-0033

Local Institution, Sapporo

105-0001

Local Institution, Minato-Ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY